Drug intelligence / Profile preview

ASC518

Development stage: Preclinical
Lead developer: ASC Therapeutics
Modality: CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
Administration: Intravenous

Overview

ASC518 is an **in vivo gene editing therapy** being developed by **ASC Therapeutics** for **hemophilia A**. It is a preclinical investigational program designed to address the underlying genetic defect responsible for factor VIII deficiency, distinguishing it from conventional factor replacement approaches and from ASC Therapeutics' separate hemophilia A gene replacement candidate. Based on the available information, ASC518 uses a gene transfer and gene editing strategy intended to correct or functionally repair the defective **F8** gene in patients with congenital hemophilia A.

Targets

F8 (Coagulation Factor VIIIa)

Beyond the preview

Go deeper on ASC518.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASC518.

Explore the full profile